Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma, Inc. reported that its planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred after a negative review by the UK Medicines and Healthcare Products Regulatory Agency. This pushes back clinical evaluation of its lead long-acting influenza antiviral in humans.
The company emphasizes that TXM previously showed potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile suited for bird flu treatment and prevention. Management stresses that influenza antivirals remain a high priority and notes a cash runway extending to Q1 2027 as it advances backup influenza candidates with similar antiviral and pharmacokinetic characteristics but designed to avoid potential regulatory concerns.
Traws Pharma, Inc. is asking stockholders to vote on key governance and equity proposals at its 2026 virtual annual meeting on July 8, 2026. Holders of 15,150,669 common shares as of May 18, 2026 can participate and vote online.
Stockholders will elect seven directors and consider amending the 2021 Incentive Compensation Plan to add 2,000,000 shares for future equity awards and make administrative updates. They are also asked to ratify KPMG LLP as auditor, approve share issuance upon exercise of Series B and Series C warrants under Nasdaq Listing Rule 5635(d), and authorize potential adjournment to gather additional votes.
Traws Pharma, Inc. reported a corporate update highlighting a new antiviral program targeting ongoing Hantavirus and Ebola Virus Disease outbreaks. The company is advancing a proprietary broad-spectrum oral combination that uses a novel “dual-strike” mechanism acting on host cell pathways, with both components already evaluated for safety in prior human studies as single agents. Non-clinical work is underway in validated Hantavirus and Ebola animal models conducted in Biosafety Level 3 and 4 laboratories, while chemical development and manufacturing are being scaled to support rapid deployment and potential stockpiling by health agencies. Traws is also engaging with organizations such as the CDC, Nigeria’s NAFDAC and the African Medicines Agency to support fast-track development and regional access, alongside its existing clinical-stage programs, including tivoxavir marboxil for influenza prevention and treatment and other investigational antivirals like ratutrelvir for COVID‑19.
Traws Pharma, Inc. reported that it may sell additional shares of common stock through its existing at-the-market equity program with Citizens JMP Securities, LLC. Under updated prospectus supplements, the company can offer shares having an aggregate offering price of up to $3,128,399, reflecting its current “baby shelf” limitation under General Instruction I.B.6. of Form S-3.
These sales would occur from time to time under the previously established At The Market Offering Agreement for up to $50,000,000 and rely on the company’s effective shelf registration statement on Form S-3 and related prospectus supplements.
TRAW amended its prospectus supplement to increase its at-the-market (ATM) capacity. Up to $3,128,399 of additional common stock, by aggregate gross sales price, may be offered and sold from time to time under the ATM Agreement with Citizens JMP Securities, LLC.
The supplement states the company previously sold 3,607,270 shares for aggregate gross proceeds of $7,710,729.46 under the ATM Agreement. It reports a $1.62 closing price on May 20, 2026 and cites an aggregate market value of common stock held by non-affiliates of $32,153,972 based on 14,483,771 shares and a March 23, 2026 price of $2.22.
Traws Pharma, Inc. is soliciting proxies for its 2026 virtual Annual Meeting to elect seven directors and ask stockholders to approve several proposals. Key items include a request to amend the 2021 Incentive Compensation Plan to increase the share reserve by 2,000,000 shares, ratify KPMG as auditor, and approve issuance of shares upon exercise of Series B and Series C warrants issued under the Securities Purchase Agreement dated April 15, 2026.
The Board recommends votes "For" the director slate and all proposals. The proxy materials and the Annual Report (including Amendment No. 1) will be made available electronically via the Notice and Access method, and the company intends to file a Form S-8 if the stockholder vote approves the Plan amendment.
Traws Pharma, Inc. files a resale prospectus registering up to 35,897,514 shares of Common Stock for resale by selling stockholders. The shares include 4,993,412 Initial Shares and up to 30,904,102 shares issuable upon exercise of Pre-Funded Warrants and Series A, B and C Warrants. The Company is not selling any shares under this prospectus and will receive no proceeds from resale; however, the Company would receive cash proceeds only if Warrants are exercised for cash. The prospectus notes a beneficial ownership limit on exercises (4.99% or, optionally, 9.99%) and describes warrant exercise conditions tied to regulatory milestones, shareholder approval and registration effectiveness. Shares outstanding were 15,150,669 as of April 24, 2026 as used for the selling-stockholder table.
Traws Pharma, Inc. reports that Perceptive Advisors and related parties hold an aggregate 6.1% stake via 979,815 warrants exercisable into Common Stock. The ownership percentage is calculated using 15,150,669 shares outstanding as of April 24, 2026. The Warrants are exercisable subject to the Beneficial Ownership Limitation, which prevents exercise if doing so would increase beneficial ownership above 9.99%.